| 000 | 00875nam a2200253 a 4500 | ||
|---|---|---|---|
| 999 |
_c3755 _d3755 |
||
| 003 | UkOxU | ||
| 005 | 20220208080129.0 | ||
| 008 | 900509s1989 enk o000 0 eng d | ||
| 020 | _a1853151106 | ||
| 040 | _cUkOxU | ||
| 050 | 0 |
_aRC374 _b.C481989 |
|
| 092 | _aD0400717473 | ||
| 111 | 2 |
_n(4th : _d1989 : |
|
| 245 | 1 | 0 |
_aFourth international symposium on sodium valproate and epilepsy : _bproceedings of a symposium sponsored by Sanofi Pharma (UK), held in St Helier, Jersey ... April, 1989 / _cedited by David Chadwick |
| 260 |
_aLondon : _bRoyal Society of Medicine Services, _c1989 |
||
| 300 | _axxix, 282 p | ||
| 504 | _aIncludes remarks | ||
| 650 | 0 |
_aEpilepsy _xChemotherapy |
|
| 650 | 0 |
_aValproic acid _xTherapeutic use |
|
| 700 | 1 |
_aChadwick, David _c(Neurologist) |
|
| 830 | 0 | _v152 | |
| 942 |
_2lcc _cBK |
||